Showing 1371-1380 of 1843 results for "".
- Allergan Rolls Out "Not Cool vs. Cool"CoolSculpting Campaign Starring Professional Male Athlete Brand Ambassadorshttps://practicaldermatology.com/news/allergan-rolls-out-not-cool-vs-coolcoolsculpting-campaign-starring-professional-male-athlete-brand-ambassadors/2457905/Allergan’s new "Not Cool vs. Cool" Multi-Channel Campaign for CoolSculpting® stars Professional Athlete Brand Ambassadors: Figure Skater Johnny Weir and Go
- Eyelid SCC On the Rise in Englandhttps://practicaldermatology.com/news/eyelid-scc-on-the-rise-in-england/2457911/Cases of a squamous cell carcinoma (SCC) in the eyelids is on the rise in England, according to new research in the British Journal of Ophthalmology. Specifically, there has been an annual increase
- Anti-IL22 Therapy May Represent New Treatment Option for Severe ADhttps://practicaldermatology.com/news/researchers-close-in-on-possible-new-treatment-for-severe-ad/2457913/New research suggests that IL-22/Th22 targeting may offer a novel treatment alternative for patients with severe atopic dermatitis (AD). The findings, which appear in the Journal of the American Academy of Dermatology, provide the first e
- Adam Friedman, MD Wins Innovations in Residency Training Awardhttps://practicaldermatology.com/news/adam-friedman-md-wins-innovations-in-residency-training-award/2457920/The Journal of Drugs in Dermatology (JDD) awarded Adam Friedman, MD, FAAD with the Innovations in Residency Training Award at the recent Orlando Dermatology Aesthetic & Clinical Conference (ODAC) held in Miami. The award recognizes individuals who have fostered innovation and i
- Desmoplastic Melanoma May Be Highly Responsive to Anti-PD-1/PD-L1 Therapieshttps://practicaldermatology.com/news/desmoplastic-melanoma-may-be-highly-responsive-to-anti-pd-1pd-l1-therapies/2457926/Patients with desmoplastic melanoma are more responsive to immune-activating anti-PD-1/PD-L1 therapies than previously assumed, Moffitt Cancer Center researchers report in the Jan. 10 issue of Nature. Pembrolizumab and niv
- AAD Issues New Guidelines for Treatment of Non-melanoma Skin Cancerhttps://practicaldermatology.com/news/aad-issues-new-guidelines-for-treatment-of-non-melanoma-skin-cancer/2457928/The American Academy of Dermatology (AAD) has addressed the growing health concern about non-melanoma skin cancers (NMSC) with the release of its guidelines of care for the management of basal cell carcinoma and cutaneous squamous cell carcinoma, published online in the Journal of the Am
- FDA Grants AbbVie's Upadacitinib Breakthrough Therapy Designation for Atopic Dermatitishttps://practicaldermatology.com/news/fda-grants-abbvies-upadacitinib-breakthrough-therapy-designation-for-atopic-dermatitis/2457932/The FDA granted Breakthrough Therapy Designation for AbbVie's investigational, once-daily oral JAK1-selective inhibitor upadacitinib (ABT-494) in adult patients with moderate to severe atopic dermatitis who are candidates for systemic therapy. This Breakthrough Therapy Designation is supporte
- Can Topical Fluorouracil Prevent Keratinocyte Carcinoma?https://practicaldermatology.com/news/can-topical-fluorouracil-prevent-keratinocyte-carcinoma/2457935/A recent study published in JAMA Dermatology found that a conventional course of fluorouracil to the face and ears substantially reduces surgery for squamous cell carcinoma for 1 year without significantly
- BridgeBio Pharma Appoints Drs. Sanuj Ravindran and Eric Michael David as CEOs-in-Residence to Lead Dermatology and Gene Therapy Programshttps://practicaldermatology.com/news/bridgebio-pharma-appoints-drs-sanuj-ravindran-and-eric-michael-david-as-ceos-in-residence-to-lead-dermatology-and-gene-therapy-programs/2457942/BridgeBio Pharma, a clinical-stage biopharmaceutical company, today announced that it has strengthened its executive leadership team with two key hires who will join the company as CEOs-in-residence. Sanuj Ravindran, MD, will serve as CEO of PellePharm, Inc. and wil
- Study: Increased Risk of Uterine Fibroids Seen in African-American Women with CCCAhttps://practicaldermatology.com/news/study-increased-risk-of-uterine-fibroids-seen-in-african-american-women-with-ccca/2457944/African-American women with central centrifugal cicatricial alopecia (CCCA) have an increased chance of developing uterine fibroids, a new study suggests. The study, which appears in the December 27 issue of JAMA Dermatology, analyzed patient data from the Johns Hopkins electroni